Payman Khales to assume the role of Integer Chief Operating Officer and Andrew Senn to become President, Cardio & Vascular in the first quarter of 2025
Integer Holdings (NYSE: ITGR) announced key leadership changes effective Q1 2025. Payman Khales, current President of Cardio & Vascular, will become Chief Operating Officer, overseeing both product categories along with Global Operations and Manufacturing Strategy. Andrew Senn will succeed Khales as President of Cardio & Vascular. Under Khales' leadership since 2018, the Cardio & Vascular business achieved above-market growth. Senn brings 18 years of experience at Integer and extensive industry knowledge from various leadership roles.
Integer Holdings (NYSE: ITGR) ha annunciato importanti cambiamenti nella leadership che entreranno in vigore nel primo trimestre del 2025. Payman Khales, attuale Presidente di Cardio & Vascular, diventerà Chief Operating Officer, supervisionando entrambe le categorie di prodotto insieme a Strategia Operativa e di Produzione Globale. Andrew Senn succederà a Khales come Presidente di Cardio & Vascular. Sotto la guida di Khales dal 2018, il business di Cardio & Vascular ha registrato una crescita superiore rispetto al mercato. Senn porta con sé 18 anni di esperienza in Integer e una vasta conoscenza del settore grazie a vari ruoli di leadership.
Integer Holdings (NYSE: ITGR) anunció cambios clave en la dirección que entrarán en vigor en el primer trimestre de 2025. Payman Khales, actual Presidente de Cardio & Vascular, se convertirá en Director de Operaciones, supervisando ambas categorías de productos junto con la Estrategia de Operaciones y Manufactura Global. Andrew Senn sucederá a Khales como Presidente de Cardio & Vascular. Bajo el liderazgo de Khales desde 2018, el negocio de Cardio & Vascular ha logrado un crecimiento superior al del mercado. Senn aporta 18 años de experiencia en Integer y un amplio conocimiento de la industria gracias a varios roles de liderazgo.
Integer Holdings (NYSE: ITGR)는 2025년 1분기부터 적용될 주요 리더십 변화를 발표했습니다. Payman Khales는 현재 심혈관 부문의 사장으로, 두 개의 제품 카테고리와 글로벌 운영 및 제조 전략을 감독하는 최고 운영 책임자로 임명됩니다. Andrew Senn은 카드 및 혈관 부문의 사장으로 Khales의 뒤를 잇습니다. Khales의 리더십 아래 2018년 이후, 심혈관 사업은 시장보다 높은 성장을 달성했습니다. Senn은 Integer에서 18년의 경험과 다양한 리더십 역할을 통해 방대한 산업 지식을 가지고 있습니다.
Integer Holdings (NYSE: ITGR) a annoncé des changements clés dans la direction, prenant effet au premier trimestre 2025. Payman Khales, président actuel de Cardio & Vascular, deviendra directeur des opérations, supervisant les deux catégories de produits ainsi que la stratégie mondiale d'opérations et de fabrication. Andrew Senn succédera à Khales en tant que président de Cardio & Vascular. Sous la direction de Khales depuis 2018, l'activité Cardio & Vascular a connu une croissance supérieure à celle du marché. Senn apporte 18 ans d'expérience chez Integer et une vaste connaissance du secteur grâce à divers rôles de leadership.
Integer Holdings (NYSE: ITGR) gab führende Änderungen bekannt, die ab dem ersten Quartal 2025 in Kraft treten werden. Payman Khales, derzeit Präsident von Cardio & Vascular, wird Chief Operating Officer und wird beide Produktkategorien sowie die globale Betriebs- und Fertigungsstrategie überwachen. Andrew Senn wird Khales als Präsident von Cardio & Vascular nachfolgen. Unter Khales' Führung seit 2018 verzeichnete das Cardio & Vascular-Geschäft ein überdurchschnittliches Wachstum. Senn bringt 18 Jahre Erfahrung bei Integer und umfassendes Branchenwissen aus verschiedenen Führungsrollen mit.
- Cardio & Vascular division has achieved above-market growth under Khales' leadership
- Internal promotion demonstrates strong succession planning and leadership continuity
- New COO role created to enhance operational excellence and best practices sharing
- None.
PLANO, Texas, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced that Payman Khales will assume the newly created role of Chief Operating Officer during the first quarter of 2025. Andrew Senn will take Mr. Khales’ place as the President, Cardio & Vascular at the same time.
Mr. Khales joined the Company in early 2018 and has served as the President, Cardio & Vascular. Under his leadership, this business has accelerated its sales and market penetration and achieved above-market growth.
As Integer’s Chief Operating Officer, Mr. Khales will oversee both of Integer’s product categories (Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation) along with Global Operations and Manufacturing Strategy. “The role of COO will be focused on sharing best practices between the product categories and enhancing the execution and speed of Integer’s global operational excellence initiatives,” said Joe Dziedzic, Integer’s President and Chief Executive Officer.
Mr. Senn has been with Integer for eighteen years, including fifteen years in our Cardio & Vascular product category, and his most recent executive role has been Senior Vice President, Strategy, Business Development, and Investor Relations. Mr. Senn will apply his deep technical knowledge and extensive leadership experience gained through program management, research and development, marketing, and sales roles at Integer and St. Jude Medical, to further guide the Cardio & Vascular product category along its growth journey.
“During his time with Integer, Payman has done an exceptional job leading the global Cardio & Vascular product category by establishing a successful market/customer-based strategy that has driven above market growth and improved profitability. With his proven expertise in commercial business leadership and his deep understanding of Integer’s product development and manufacturing operations, he is uniquely positioned to take on a greater responsibility within the Company,” said Mr. Dziedzic. He added, “Andrew has served successfully in many roles at Integer, from research and development to sales to the head of corporate strategy. He has a deep knowledge of the industry and a strong customer focus and is ideally suited to continue the growth of our Cardio & Vascular business.”
Mr. Khales said, “I am honored to become Integer’s Chief Operating Officer and look forward to working closely with Jim Stephens (President CRM&N), John Harris (EVP, Global Operations and Manufacturing Strategy) and Andrew in his new role. Together we will continue to serve our customers through development of high-quality complex products and processes, achieving above-market growth over the long term.”
Before joining Integer, Mr. Khales served as President of the Environmental Technologies business segment for CECO Environmental Corp., a diversified global provider of engineered technologies to the environmental, energy, and fluid handling and filtration industrial segments. Prior to that, he held several progressive executive leadership roles at Ingersoll Rand Company.
Mr. Khales holds an Executive Master of Business Administration from Indiana University’s Kelley School of Business, and a Bachelor of Science in Mechanical Engineering from École Polytechnique de Montréal.
Mr. Senn was Director of Program Management responsible for electrophysiology systems at St. Jude Medical prior to joining Integer.
Mr. Senn holds a Master of Business Administration with concentrations in Finance, Marketing and Medical Industry Leadership from the Carlson School of Management at the University of Minnesota and a Master of Science in Technology Management, Bachelor of Science in Mechanical Engineering and a Bachelor of Arts in Business Administration from the University of St. Thomas.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, Integer is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
| Investor Relations: Andrew Senn andrew.senn@integer.net 763.951.8312 | Media Relations: Kelly Butler kelly.butler@integer.net 469.731.6617 |
FAQ
When will Payman Khales become COO of Integer Holdings (ITGR)?
Who will replace Payman Khales as President of Cardio & Vascular at Integer (ITGR)?
What has been Integer's (ITGR) Cardio & Vascular division performance under Payman Khales?
